AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00927589
Drug: trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous repeating dose
Trial: NCT03327701
Drug: Benralizumab
RxNorm normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
Trial: NCT01224405
Drug: Docetaxel + LH-RH analogues
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.~In patients randomised to arms A up to 10 cycles of docetaxel will be planned in association to maintenance of LH-RH analogues administration.
Trial: NCT01224405
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.~In patients randomised to arms B up to 10 cycles of docetaxel will be planned, in association to stopping LH-RH analogues.
Trial: NCT01224405
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomised in the arms AB1 (intermittent docetaxel) will suspend treatment after at least 4 cycles if their PSA level will be reduced \>50%. Docetaxel treatment will be resumed when the serum PSA will rise by \>50% from the lowest PSA level recorded and will be \>10 ng/mL or when there will be other evidence of disease progression. PSA progression must to be confirmed with a second assessment after 2 weeks before deciding to resume docetaxel administration.
Trial: NCT01224405
Drug: Continuous Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomised in the arms AB2 (continuous docetaxel) will continue treatment up to ten cycles after even if their PSA level at 4 cycles will be reduced \>50% or will reach a level \<4 ng/mL.
Trial: NCT01224405
Drug: Continuous Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomised in the arms AB1(intermittent docetaxel) will continue treatment up to ten cycles even if their PSA level after 4 cycles will be reduced \>50% or will reach a level \<4 ng/mL.
Trial: NCT00021385
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00021385
Drug: squalamine lactate
RxNorm normalized name: Squalamine
DrugBank: Squalamine (DB06461)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03582462
Drug: IONIS FXI-LRx
RxNorm normalized name: IONIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection
Trial: NCT02897778
Drug: Entinostat
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, supratherapeutic dose of entinostat given orally.
Trial: NCT01090778
Drug: Norditropin SimpleXx (growth hormone)
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg/subject/day over two consecutive days
Trial: NCT04173507
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04173507
Drug: Talazoparib
RxNorm normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04173507
Drug: Talazoparib Tosylate
RxNorm normalized name: TALAZOPARIB TOSYLATE
DrugBank: Talazoparib (DB11760)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT03260556
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Increasing doses
Trial: NCT01050829
Drug: Gadobutrol (Gadovist, BAY86-4875)
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single administration at a dose of 0.1 mmol/kg
Trial: NCT01050829
Drug: Gadopentetate Dimeglumine (Magnevist, BAY86-4882)
DrugBank: Gadopentetic acid (DB00789)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single administration at a dose of 0.1 mmol/kg
Trial: NCT02880670
Drug: BMS-986142
RxNorm normalized name: BMS-986142
DrugBank: BMS-986142 (DB15291)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01866826
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subject will receive three capsules of rifaximin (183.3 mg each) by mouth twice daily (total 1100 mg Daily)
Trial: NCT01687894
Drug: Vasopressins
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressins propofol vasopressins sevoflurane
Trial: NCT01687894
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vasopressin propofol \& placebo propofol
Trial: NCT01687894
Drug: sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vasopressins sevoflurane placebo sevoflurane
Trial: NCT01662778
Drug: 6 microns at 50mg
RxNorm normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STAG generated monodisperse 6 micron particles
Trial: NCT01662778
Drug: MDI FP
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
DrugBank: Albutrepenonacog alfa (DB13884)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT03203967
Drug: Intravenous morphine analgesia
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/ml morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 ml/h.
Trial: NCT01133730
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine
Trial: NCT03370640
Drug: SEP-363856
RxNorm normalized name: SEP-363856
DrugBank: SEP-363856 (DB15665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral 25 or 50mg dose of SEP 363856
Trial: NCT04582032
Drug: Dexketoprofen (KETAVEL 50 mg/2 ml)
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous dexketoprofen (KETAVEL 50 mg/2 ml)
Trial: NCT04582032
Drug: Saline (Isotonic Saline Solution 0.9% )
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous 2 ml of saline
Trial: NCT01983267
Drug: cannabis
RxNorm normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use of cannabis oil or cigarets
Trial: NCT00241670
Drug: 5-aminolevulinic acid (5-ALA)
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 grams 5-ALA dissolved in 50 ml water, single dose, orally, 2-4 hours prior to surgery
Trial: NCT00280735
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be given intravenously,once,every 3 weeks. The carboplatin area under curve (AUC) dose will be calculated using the Calvert Equation 19 as follows: Carboplatin dose (mg) = 6x (GFR + 25)
Trial: NCT00280735
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m² intravenously, once, every 3 weeks
Trial: NCT03203317
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 h insulin clamp
Trial: NCT03388151
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg till reaching satisfactory level of sedation
Trial: NCT03388151
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v till reaching satisfactory level of sedation
Trial: NCT00955929
Drug: Placebo QHS and sildenafil and questionnaires
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pts will be offered sildenafil 100 mg to be used before intercourse on an as-required basis. They will be given six 100 mg doses, per month, for a 12-month duration. Each patient in this group will use a placebo pill (blinded) each night, except on a nights that 100mg is taken for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
Trial: NCT00955929
Drug: Sildenafil and questionnaire
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window
Trial: NCT00955929
Drug: Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires
RxNorm normalized name: coagulation factor IX, II, VII and X in combination
DrugBank: Factor IX Complex (Human) (DB11330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernous injections of a trimix combination (Papaverine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL) will be injected three times a week, and sildenafil 50mg taken on the other four (non-injection) nights. Injection therapy can be used for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
Trial: NCT00876889
Drug: Riluzole
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg PO (by mouth) every 12 hours starting within 12 hours of injury and continuing for 14 days (28 doses).
Trial: NCT03983980
Drug: Tapinarof
RxNorm normalized name: Tapinarof
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapinarof cream, 1%, applied once daily
Trial: NCT00190762
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01342081
Drug: DE-111 ophthalmic solution
RxNorm normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01342081
Drug: Tafluprost ophthalmic solution 0.0015%
DrugBank: Tafluprost (DB08819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01342081
Drug: Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00839358
Drug: albumin
RxNorm normalized name: Albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albumine 40 g every 15 days
Trial: NCT00839358
Drug: Midodrine
RxNorm normalized name: Midodrine
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Midodrine 5mg/8 hs, can be increase up to 8mg/8hs if there is a lack of increase in at least 10mmHg in mean arterial pressure after 15 days of treatment.
Trial: NCT00354913
Drug: hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea is administered orally twice a day. The dose will be set at 500 mg twice a day for all patients. If vomiting occurs not additional trial medication should be taken that day in an effort to replace the material that has been vomited. It is recommended that patients take their prescribed hydroxyurea at the same time that they take their prescribed imatinib mesylate, however, a 30-60 minute interval between agents is acceptable, if required for practical or other compliance issues.
Trial: NCT00354913
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib administered orally on daily, continuous basis. Imatinib doses of 400mg/600mg administered once daily, whereas daily doses of 800mg/greater administered as equally divided dose taken twice day.~Dose for Imatinib:~Patients receiving p450-inducing antiepileptic drugs:500mg twice day Patients not receiving p450-inducing antiepileptic drugs:400mg/day.~If patients who were not on Cytochrome P450, family 3, subfamily A (CYP3A) enzyme-reducing anti-epileptic drug (EIAED) when originally enrolled must initiate CYP3A enzyme-inducing anti-epileptic drug while on study, study regimen will remain same for minimum of 2 wks before pt transitions to dosing as specified for patients on anti-epileptic drug. If patients originally enrolled must discontinue all EIAEDs while on study, in interest of patient safety, dosing of study regimen will transition to that of patients not on anti-epileptics immediately.
Trial: NCT03727074
Drug: 5-FU Cream
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: topical cream twice a day
Trial: NCT01163201
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously on Days -8 through -6, 25 mg/m\^2 over 1 hour
Trial: NCT03209271
Drug: Ringer's Acetate (warm)
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body temperature fluid
Trial: NCT03209271
Drug: Ringer's Acetate (cold)
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature fluid
Trial: NCT02783924
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D preparation
Trial: NCT03530683
Drug: Maplirpacept (PF-07901801)
RxNorm normalized name: Maplirpacept
DrugBank: Maplirpacept (DB18441)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maplirpacept (PF-07901801) will be administered by intravenous infusion at ranging doses, as determined from sequential dosing cohorts.
Trial: NCT03530683
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous (IV) or subcutaneous (SC) daily for 7 days, repeated every 4 weeks
Trial: NCT03530683
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: orally daily for each day of each cycle (first 7 doses taken in clinic). The ramp-up and target dose of venetoclax will be adjusted per the package insert in subjects who are taking concomitant moderate or strong CYP3A4 inhibitors or posaconazole
Trial: NCT03530683
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days 1, 8, and 15 of 28-day cycles; starting dose IV given on Cycle (C) 1 Day (D) 1, and if tolerated, then increased dose via IV given starting on C1D8 and subsequent doses thereafter.
Trial: NCT03530683
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: starting dose via IV on Days 1, 8, 15, and increased dose via IV on 28-day cycles
Trial: NCT03530683
Drug: Anti-CD20 Targeting agent
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The anti-CD20 targeting agent will be administered for a total of eight doses, and then Cohort F1, F2 and F3: TTI-622 + isatuximab, carfilzomib and dexamethasone Cohort C1, C2 and C3: TTI-622 + Carfilzomib and Dexamethasone will be continued as single-agent therapy.
Trial: NCT03530683
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: F1: IV dose C0D1, C0D8, C0D15 and C0D22 (lead in phase);weekly during Cycle 1; Cycle 2 and beyond will be administered on Days 1 and 15 (Q2W).~F2 and F3: IV dose C0D1 and C0D8 (lead in phase); C1D1, C1D8, C1D15 and C1D22; Cycle 2 and beyond will be administered on days 1 and 15 (Q2W). Carfilzomib: IV dose on days 1 and 2 of cycle 1; then increased IV dose on days 8, 9, 15, and 16 of cycle 1; cycle 2 and beyond: increased IV dose on days 1, 2, 8, 9, 15, and 16. Dexamethasone IV or PO on days 1, 2, 8, 9, 15, 16, 22, and 23 starting cycle 1.
Trial: NCT02265393
Drug: OTO-104
RxNorm normalized name: DB-OTO
DrugBank: DB-OTO (DB18278)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01629511
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01629511
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT01629511
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01629511
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02496182
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1800 mg
Trial: NCT02496182
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1200 mg
Trial: NCT00942357
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00942357
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00942357
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00428701
Drug: Esomeprazole Sodium
RxNorm normalized name: Esomeprazole Sodium
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03817125
Drug: Vancomycin pretreatment
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin (125mg) will be administered orally four times a day, followed by a 2-3 day washout.
Trial: NCT03817125
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (480 mg) will be administered intravenously (IV) according to institutional guidelines every 4 weeks for up to 12 cycles. A cycle is defined as 4 calendar weeks.
Trial: NCT03817125
Drug: SER-401
RxNorm normalized name: Ser
DrugBank: Serine (DB00133)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.
Trial: NCT02016534
Drug: AMG 337
RxNorm normalized name: AMG-337
DrugBank: AMG-337 (DB15639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 337 300mg orally daily.
Trial: NCT01582035
Drug: TVR
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: type=exact number, unit= mg, number=1125, form=tablet, route=oral use. TVR is to be taken twice daily at a dose of 1125 mg for 10 days.
Trial: NCT01582035
Drug: TVR
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: type=exact number, unit=mg, number=1125 or 1500, form=tablet, route=oral use. In panel 2: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 10 or 14 days. In panel 3: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 6 days with on day 6 a morning dose only.
Trial: NCT01582035
Drug: TVR
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: type= exact number, unit= mg, number=750, form=tablet, route=oral use. TVR is to be taken every 8 hours at a dose of 750 mg for 12 weeks.
Trial: NCT01582035
Drug: RBV
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: type=exact number, unit=mg, number=1000 or 1200, form=tablet, route=oral use. RBV is to be taken at 1000 or 1200 mg per day in 2 divided doses, depending on the weight for 24 or 48 weeks.
Trial: NCT00247715
Drug: algeldrate/magnesium oxide
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00247715
Drug: ranitidine
RxNorm normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no